文献速递中枢神经肿瘤放疗胸部肿瘤放疗

PD-L1表达可能独立预测接受免疫治疗的非小细胞肺癌脑转移患者生存

Programmed Death Receptor Ligand One Expression May Independently Predict Survival in Patients With Non-Small Cell Lung Carcinoma Brain Metastases Receiving Immunotherapy.
PubMed 文献 · Int J Radiat Oncol Biol Phys · 2020-04-23

PURPOSE: Programmed death receptor ligand 1 (PD-L1) expression is known to predict response to PD-1/PD-L1 inhibitors in non-small cell lung cancer (NSCLC). However, the predictive role of this biomarker in brain metastases (BMs) is unknown.…

核心结论

  • 在接受PD-1/PD-L1抑制剂联合局部治疗的非小细胞肺癌脑转移患者中,PD-L1表达可能独立于肺分级预后评估预测总生存。
  • PD-L1表达与颅内无进展生存无显著关联,但分析可能把握度不足。

研究设计与样本

  • 患者在接受脑转移局部治疗(放疗或神经外科手术)后、颅内进展前接受PD-1/PD-L1抑制剂治疗。
  • 采用Cox比例风险模型评估PD-L1表达对总生存和颅内无进展生存的预测价值。

临床怎么用

  • 对非小细胞肺癌脑转移患者,PD-L1表达状态可能有助于筛选从PD-1/PD-L1抑制剂联合局部治疗中总生存获益的人群。
  • PD-L1表达不宜单独用于预判颅内无进展生存,需结合其他临床因素综合评估。

局限性

  • 回顾性设计,需更大规模研究验证PD-L1在脑转移中的预测价值。

以上解读依据论文摘要(全文未开放获取或许可不允许翻译转载)。

原文

PURPOSE: Programmed death receptor ligand 1 (PD-L1) expression is known to predict response to PD-1/PD-L1 inhibitors in non-small cell lung cancer (NSCLC). However, the predictive role of this biomarker in brain metastases (BMs) is unknown. The aim of this study was to assess whether PD-L1 expression predicts survival in patients with NSCLC BMs treated with PD-1/PD-L1 inhibitors, after adjusting for established prognostic models. METHODS AND MATERIALS: In this multi-institutional retrospective cohort study, we identified patients with NSCLC-BM treated with PD-1/PD-L1 inhibitors after local BM treatment (radiation therapy or neurosurgery) but before intracranial progression. Cox proportional hazards models were used to assess the predictive value of PD-L1 expression for overall survival (OS) and intracranial progression-free survival (IC-PFS). RESULTS: Forty-eight patients with BM with available PD-L1 expression were identified. PD-L1 expression was positive in 33 patients (69%). Median survival was 26 months. In univariable analysis, PD-L1 predicted favorable OS (hazard ratio [HR], 0.44; 95% confidence interval [CI], 0.19-1.02; P = .055). This effect persisted after correcting for lung-graded prognostic assessment and other identified potential confounders (HR, 0.24; 95% CI, 0.10-0.61; P = .002). Moreover, when modeled as a continuous variable, there appeared to be a proportional relationship between percentage of PD-L1 expression and survival (HR, 0.86 per 10% expression; 95% CI, 0.77-0.98; P = .02). In contrast, PD-L1 expression did not predict IC-PFS in uni- or multivariable analysis (adjusted HR, 0.54; 95% CI, 0.26-1.14; P = .11). CONCLUSIONS: In patients with NSCLC-BMs treated with PD-1/PD-L1 checkpoint inhibitors and local treatment, PD-L1 expression may predict OS independent of lung-graded prognostic assessment. IC-PFS did not show association with PD-L1 expression, although the present analysis may lack power to assess this. Larger studies are required to validate these findings.

来源:Int J Radiat Oncol Biol Phys,查看原文。版权归原作者所有。

引用

  1. Hulsbergen AFC, Mammi M, Nagtegaal SHJ, et al. Programmed Death Receptor Ligand One Expression May Independently Predict Survival in Patients With Non-Small Cell Lung Carcinoma Brain Metastases Receiving Immunotherapy. Int J Radiat Oncol Biol Phys. 2020. PMID: 32335185. doi:10.1016/j.ijrobp.2020.04.018

供执业医师工作参考,不替代临床判断;数值与分级以指南原文为准。